VEGFA and ovarian carcinoma: A recent study investigating adaptive resistance to anti-VEGF antibody therapy in ovarian cancer found that, in anti-VEGF antibody-resistant tumors, BARD1 expression was downregulated and associated with increased promoter methylation.